Cargando…
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253893/ https://www.ncbi.nlm.nih.gov/pubmed/19325518 http://dx.doi.org/10.3390/molecules14031183 |
_version_ | 1783373598678843392 |
---|---|
author | Robak, Tadeusz Korycka, Anna Lech-Maranda, Ewa Robak, Pawel |
author_facet | Robak, Tadeusz Korycka, Anna Lech-Maranda, Ewa Robak, Pawel |
author_sort | Robak, Tadeusz |
collection | PubMed |
description | For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials. |
format | Online Article Text |
id | pubmed-6253893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Molecular Diversity Preservation International |
record_format | MEDLINE/PubMed |
spelling | pubmed-62538932018-11-30 Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases Robak, Tadeusz Korycka, Anna Lech-Maranda, Ewa Robak, Pawel Molecules Review For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been synthesized and become available for either in vitro studies or clinical trials. Among them the class of antineoplastic drugs belonging to the purine nucleoside analogues group (PNAs) plays an important role. Three of them: pentostatin (DCF), cladribine (2-CdA) and fludarabine (FA) were approved by Food and Drug Administration (FDA) for the treatment of hematological malignancies. Recently three novel PNAs: clofarabine (CAFdA), nelarabine (ara-G) and forodesine (immucillin H, BCX-1777) have been synthesized and introduced into preclinical studies and clinical trials. These agents seem to be useful mainly for the treatment of human T-cell proliferative disorders and they are currently undergoing clinical trials in lymphoid malignancies. However, there are also several studies suggesting the role of these drugs in B-cell malignancies. This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials. Molecular Diversity Preservation International 2009-03-23 /pmc/articles/PMC6253893/ /pubmed/19325518 http://dx.doi.org/10.3390/molecules14031183 Text en © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Robak, Tadeusz Korycka, Anna Lech-Maranda, Ewa Robak, Pawel Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title | Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title_full | Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title_fullStr | Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title_full_unstemmed | Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title_short | Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases |
title_sort | current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253893/ https://www.ncbi.nlm.nih.gov/pubmed/19325518 http://dx.doi.org/10.3390/molecules14031183 |
work_keys_str_mv | AT robaktadeusz currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases AT koryckaanna currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases AT lechmarandaewa currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases AT robakpawel currentstatusofolderandnewpurinenucleosideanaloguesinthetreatmentoflymphoproliferativediseases |